These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 27196332

  • 1. An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
    M Llibre J, Raffi F, Moyle G, Behrens G, Bouee S, Reilly G, Borg P, Piontkowsky D, Rogatto F.
    PLoS One; 2016; 11(5):e0155406. PubMed ID: 27196332
    [Abstract] [Full Text] [Related]

  • 2. An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine.
    Rogatto F, Bouee S, Jeanbat V, Piontkowsky D, Aragao F, Bosse M.
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19779. PubMed ID: 25397523
    [Abstract] [Full Text] [Related]

  • 3. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
    Patel DA, Snedecor SJ, Tang WY, Sudharshan L, Lim JW, Cuffe R, Pulgar S, Gilchrist KA, Camejo RR, Stephens J, Nichols G.
    PLoS One; 2014; 9(9):e105653. PubMed ID: 25188312
    [Abstract] [Full Text] [Related]

  • 4. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
    Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H, GS-US-380-1489, GS-US-380-1490 study investigators.
    Lancet HIV; 2020 Jun; 7(6):e389-e400. PubMed ID: 32504574
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
    Baldin G, Ciccullo A, Capetti A, Rusconi S, Sterrantino G, Cossu MV, Giacomelli A, Lagi F, Latini A, Bagella P, De Luca A, Di Giambenedetto S, Madeddu G.
    HIV Med; 2019 Feb; 20(2):164-168. PubMed ID: 30457197
    [Abstract] [Full Text] [Related]

  • 6. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, López-Cortés L, Ruane P, Podzamczer D, Brinson C, Custodio J, Liu H, Andreatta K, Martin H, Cheng A, Quirk E.
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [Abstract] [Full Text] [Related]

  • 7. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
    Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E.
    Lancet; 2017 Nov 04; 390(10107):2063-2072. PubMed ID: 28867497
    [Abstract] [Full Text] [Related]

  • 8. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
    Moreno Guillen S, Losa García JE, Berenguer Berenguer J, Martínez Sesmero JM, Cenoz Gomis S, Graefenhain R, Lopez Sanchez-Cambronero D, Parrondo Garcia FJ.
    Farm Hosp; 2017 Sep 01; 41(5):601-610. PubMed ID: 28847249
    [Abstract] [Full Text] [Related]

  • 9. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G, SINGLE Investigators.
    N Engl J Med; 2013 Nov 07; 369(19):1807-18. PubMed ID: 24195548
    [Abstract] [Full Text] [Related]

  • 10. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP.
    AIDS; 2011 Mar 27; 25(6):F7-12. PubMed ID: 21412057
    [Abstract] [Full Text] [Related]

  • 11. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
    Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A, Buchanan AM, Wynne B, Vavro C, Aboud M, Smith KY, ARIA study team.
    Lancet HIV; 2017 Dec 27; 4(12):e536-e546. PubMed ID: 28729158
    [Abstract] [Full Text] [Related]

  • 12. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Wohl DA, Yazdanpanah Y, Baumgarten A, Clarke A, Thompson MA, Brinson C, Hagins D, Ramgopal MN, Antinori A, Wei X, Acosta R, Collins SE, Brainard D, Martin H.
    Lancet HIV; 2019 Jun 27; 6(6):e355-e363. PubMed ID: 31068270
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
    Peng S, Tafazzoli A, Dorman E, Rosenblatt L, Villasis-Keever A, Sorensen S.
    J Med Econ; 2015 Jun 27; 18(10):763-76. PubMed ID: 25934146
    [Abstract] [Full Text] [Related]

  • 14. A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals.
    Moyle GJ, Orkin C, Fisher M, Dhar J, Anderson J, Wilkins E, Ewan J, Ebrahimi R, Wang H, ROCKET 1 (Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial) Study Group.
    PLoS One; 2015 Jun 27; 10(2):e0116297. PubMed ID: 25658097
    [Abstract] [Full Text] [Related]

  • 15. Similar Durability of Two Single Tablet Regimens, Dolutegravir/Abacavir/Lamivudine and Elvitegravir/Cobicistat/Tenofovir/Emtricitabine: Single Center Experience.
    Chin BS, Lee JH, Kim G.
    J Korean Med Sci; 2020 Jul 27; 35(29):e235. PubMed ID: 32715668
    [Abstract] [Full Text] [Related]

  • 16. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
    Greig SL, Deeks ED.
    Drugs; 2015 Apr 27; 75(5):503-14. PubMed ID: 25698454
    [Abstract] [Full Text] [Related]

  • 17. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
    Hodder S, Squires K, Kityo C, Hagins D, Avihingsanon A, Kido A, Jiang S, Kulkarni R, Cheng A, Cao H.
    J Acquir Immune Defic Syndr; 2018 Jun 01; 78(2):209-213. PubMed ID: 29481486
    [Abstract] [Full Text] [Related]

  • 18. Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.
    Jiang J, Xu X, Guo W, Su J, Huang J, Liang B, Chen H, Zang N, Liao Y, Ye L, Liang H.
    AIDS Res Ther; 2016 Jun 01; 13(1):30. PubMed ID: 27617024
    [Abstract] [Full Text] [Related]

  • 19. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.
    White KL, Kulkarni R, McColl DJ, Rhee MS, Szwarcberg J, Cheng AK, Miller MD.
    Antivir Ther; 2015 Jun 01; 20(3):317-27. PubMed ID: 25321623
    [Abstract] [Full Text] [Related]

  • 20. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
    Giacomelli A, Conti F, Pezzati L, Oreni L, Ridolfo AL, Morena V, Bonazzetti C, Pagani G, Formenti T, Galli M, Rusconi S.
    BMC Infect Dis; 2021 Jun 22; 21(1):595. PubMed ID: 34157984
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.